Investigating the causal relationships between excess adiposity and cardiometabolic health in men and women
Mutie PM, Pomares-Milan H, Atabaki-Pasdar N, et al.
Diabetologia. Pub. online 12 Oct 2022.
Leggi
Blu
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
New strategies to improve clinical outcomes for diabetic kidney disease
Forst T, Mathieu C, Giorgino F, et al.
BMC Med. 2022;20(1):337.
Leggi
Statin use and risk of diabetes by subclinical atherosclerosis burden (from a multi-ethnic study of atherosclerosis report)
Rifai MA, Szklo M, Patel J, et al.
Am J Cardiol. 2022;S0002-9149(22)00958-4.
Leggi
Retinal artery occlusion as an early indicator of macrovascular complications in diabetes
Ørskov M, Vorum H , Bjerregaard Larsen T, et al.
Am J Med. 2022;S0002-9343(22)00723-9.
Leggi
Characteristics and outcomes of patients with type 1 diabetes admitted with acute coronary syndromes
Nejatian MM, Lan NSR, Yeap BB, et al.
Diabetes Res Clin Pract. 2022;192:110093.
Leggi
Intermittently scanned continuous glucose monitoring for type 1 diabetes
Leelarathna L, Evans ML, Neupane S, et al.
N Engl J Med. Pub. online 5 Oct 2022.
Leggi
Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper
Faggiano A, Mazzilli R, Natalicchio A, Adinolfi V, Argentiero A, Danesi R, D’Oronzo S, Fogli S, Gallo M, Giuffrida D, Gori S, Montagnani M, Ragni A, Renzelli V, Russo A, Silvestris N, Franchina T, Tuveri E, Cinieri S, Colao A, Giorgino F, Zatelli MC
Crit Rev Oncol Hematol. 2022;180:103826.
Leggi
Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study
Gregory GA, Robinson TIG, Linklater SE, et al.
Lancet Diabetes Endocrinol. 2022;10(10):741-760.
Leggi
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
Heerspink HJL, Sattar N, Pavo I, et al.
Lancet Diabetes Endocrinol. 2022;S2213-8587(22)00243-1.
Leggi
Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis
Yang S, Zhao L, Mi Y, He W
Diabetes Obes Metab. 2022;24(11):2159-2168.
Leggi